NCT00763347 - Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

SYR-619

SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

SYR-619

SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

SYR-619

SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

SYR-619

SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Placebo

SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.